로딩 중...
52주 최고가 대비 67.9% 위치
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
SEC 13F 공시 기준 · 2025-Q2
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|
| 주요 재무실적 (USD) | ||||
| 매출액 | $0 | $0 | $0 | $0 |
| 영업이익 | $-70.4M | $-100.8M | $-150.9M | $-393.3M |
| 당기순이익 | $-68.9M | $-85.9M | $-110.0M | $-359.6M |
| 잉여현금흐름 (FCF) | $-48.4M | $-73.4M | $-87.8M | $-278.7M |
| 수익성 비율 | ||||
| 영업이익률 | - | - | - | - |
| 순이익률 | - | - | - | - |
| ROE (자기자본이익률) | -47.4% | -24.7% | -12.5% | -56.3% |
| ROA (자산이익률) | -40.9% | -23.3% | -12.1% | -50.2% |
| 성장성 비율 | ||||
| 매출 성장률 (YoY) | - | - | - | - |
| EPS 성장률 (YoY) | - | -1.1% | -11.0% | -215.8% |
| 투자 지표 & 가치배수 | ||||
| PER (주가수익배수) | - | - | - | - |
| PBR (주가순자산배수) | 7.0x | 8.0x | 4.3x | 5.3x |
| PSR (주가매출배수) | - | - | - | - |
| FCF Yield | -4.8% | -2.6% | -2.3% | -8.3% |
| 재무 건전성 (안정성) | ||||
| 부채비율 (D/E) | 0.01 | 0.00 | 0.00 | 0.00 |
| 유동비율 | 7.61 | 19.19 | 33.09 | 9.33 |
MOLINA HEALTHCARE INC
$179.86
$9.4B